A lthough there are some exceptions, 1,2 numerous publications support the counterregulatory roles of the angiotensin II type 2 receptor (AT 2 ) against the AT 1 receptor functions, such as inhibition of vascular contraction and hypertrophy. [3] [4] [5] However, it is still very uncertain as to how the AT 2 receptor signals interfere with those of the AT 1 receptor in the cardiovascular system. 5, 6 Past findings suggest that the signal transduction of AT 1 inhibition by the AT 2 receptor may involve multiple distinct mechanisms. Some of these mechanisms appear to be indirect, such as production of nitric oxide through bradykinin opposing the vasoconstrictor actions of the AT 1 receptor. 3 The direct inhibitory crosstalk of the 2 receptors occurs proximal to the receptor heterodimerization, as well as downstream from the receptors between AT 1 -activated protein kinases epidermal growth factor receptor kinase and extracellular signal-regulated kinase (ERK)1/ 2/p42/44 mitogen-activated protein kinase (MAPK), etc and AT 2 -activated protein phosphatases protein phosphatase 2A, SHP-1, and MAPK phosphatase-1. 7, 8 The activation of the protein phosphatases by the AT 2 receptor may or may not require heterotrimeric G proteins (G i or G s ) and/or the recently identified AT 2 receptor C-terminal tail-interacting proteins. 4 -6 Given that induction of hypertrophy of vascular smooth muscle cells (VSMCs) via the AT 1 receptor appears to require a "triple-membrane-passing signal" involving a metalloprotease-dependent epidermal growth factor receptor transactivation, 9,10 the article by Guilluy et al in this issue of Circulation Research 11 may not be so surprising, because it suggests the requirement of rather "twisty" 3 sequential phosphorylation/dephosphorylation events between a phosphatase, SHP-1, and 2 protein kinases for RhoA inhibition by the AT 2 receptor (see Figure 7 in the article). Although negative regulation of RhoA through its Ser188 phosphorylation by the AT 2 receptor has been demonstrated, 12,13 the 2 kinases (casein kinase II [CK2] and Ste20-related kinase SLK) are novel downstream elements of the AT 2 receptor.
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By using multiple distinct molecular approaches, a novel signal transduction cascade for inhibition of RhoA via the AT 2 receptor, which is expected to counterregulate RhoA activation by the AT 1 receptor in VSMCs, becomes apparent ( Figure) . 11 Rho kinase (ROCK), the best-characterized effector of the small G protein RhoA, contributes to vascular contraction via Ca 2ϩ sensitization. Moreover, the Rho/ROCK pathway has been implicated in a wide variety of cardiovascular pathogenic conditions, including hypertension, atherosclerosis, and cardiovascular hypertrophy. 14 -17 It should be noted that both heterotrimeric G protein-dependent and -independent signal transductions have been proposed to mediate AT 1 receptor function. 4, 18, 19 In addition to the production of reactive oxygen species 4 and enhanced VSMC contraction, hypertrophy, as well as migration induced by the AT 1 receptor, seems to require at least two parallel signal transduction cascades mediated through G q and G 12/13 . The latter is primarily implicated in the Rho/ROCK cascade activation via RGS (regulator of G protein signaling)-domain containing Rho guanine nucleotide exchange factors (RhoGEFs). 20 -23 Inhibition of either cascade appears to block those pathogenic functions induced by the AT 1 receptor, 20 -23 and the study by Guilluy et al 11 has further demonstrated that the RhoA inhibition mechanism via the AT 2 receptor in VSMCs results in vasodilation. 11 The findings also indicate a strong support of this potential "triple twist" RhoA inhibition theory to explain the multiple tissue protective effects of AT 1 receptor blockers beyond the expected AT 1 inhibition, because the AT 2 receptors could be strongly stimulated under these treatments.
In addition, identification of the novel key components of the AT 2 signal transduction will aid in exploring the molecular insight regarding the dynamic regulation of cardiovascular remodeling via the AT 1 versus AT 2 , which likely involves far more additional crosstalk. Both cAMP-and cGMP-dependent kinases have been shown to phosphorylate RhoA at Ser188, 24 which, in part, explains the vasodilatory properties of these kinases in VSMCs. The study by Guilluy et al has identified SLK as a novel RhoA Ser188 kinase. 11 Interestingly, SLK has been shown to be able to activate apoptosis signal-regulated kinase-1 (ASK1) and p38 MAPK, leading to cell apoptosis. 25 This fits well with the past findings that AT 2 mediates apoptosis in VSMCs via p38 MAPK activation. 26 Regarding CK2, activation of CK2 has been recently shown to mediate p27 degradation by angiotensin II likely through the AT 1 receptor, which leads to cardiac hypertrophy. 27 The p27 degradation has also been implicated in vascular hyperplasia. 28 Therefore, inhibition of CK2 activity by the AT 2 receptor may also antagonize the AT 1 mediated detrimental effects through stabilization of p27 in addition to the RhoA inhibition.
Because the findings by Guilluy et al 11 were mostly limited to VSMC culture and a ex vivo deendothelialized contraction assay using rat thoracic aorta rings, the relevance of this novel AT 2 signal transduction in mediating the beneficial AT 2 function in cardiovascular diseases remains unclear. Further expansion of the research in this field by using animal models of cardiovascular diseases has strong potential for future translation of the outcomes, which may lead to prevention of cardiovascular diseases linked to enhanced AT 1 receptor signal transduction.
Figure.
Novel signal transduction cross-talk between AT 1 and AT 2 in VSMCs. The Rho/Rhokinase cascade inhibition by the AT 2 receptor via the "triple-twist" theory involving SHP-1, CK2, and SLK not only inhibits AT 1 -induced vascular contraction but also likely inhibits VSMC hypertrophy and migration. In addition, CK2 may be activated through the AT 1 receptor, and AT 2 -activated SHP-1 has been shown to directly inactivate epidermal growth factor receptor (EGFR) to inhibit AT 1 -activated hypertrophic signal transduction. ARB indicates angiotensin II receptor blocker.
